Traws Pharma Shares Drop 16.4% After UK Regulators Reject Phase 2a Study
TRAW•Traws Pharma stock fell 16.4% after the UK's Medicines and Healthcare Products Regulatory Agency issued a negative review of its Phase 2a influenza challenge study, forcing postponement of the pivotal trial for its lead antiviral candidate, tivoxavir marboxil. This postpones critical data readouts and pushes back the antiviral's development.
1. Regulatory Setback
Traws Pharma disclosed that the UK's Medicines and Healthcare Products Regulatory Agency issued a negative review of its Phase 2a influenza challenge study, forcing a postponement of the pivotal trial for its lead antiviral candidate, tivoxavir marboxil.
2. Development and Timeline Impact
The delay halts planned data readouts and pushes back the antiviral's overall development timeline, increasing uncertainty around clinical milestones and potential regulatory approval path for Traws Pharma's influenza program.
